E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Heart failure |
srdeční selhání |
|
E.1.1.1 | Medical condition in easily understood language |
Heart failure |
srdeční selhání |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Decrease in arrhythmia incidence in heart failure patients using ivabradine |
Snížení výskytu arytmií u pacientů se srdečním selháním, užívajících ivabradin |
|
E.2.2 | Secondary objectives of the trial |
Antiremodelation effect on left ventricle |
Antiremodelační efekt na levou komoru |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
adults with ICD and EF ≤35% a resting heart rate > 75/min with a standard up-titrated HF treatment (diuretics, verospiron, betablockers, ACEI) |
dospělí pacienti s ICD a EF ≤35% a klidovou sinusovou frekvencí > 75/min se standardní vytitrovanou léčbou diuretiky, ACE inhibitory, betablokátory a verospironem do tolerovaného maxima |
|
E.4 | Principal exclusion criteria |
permanent atrial fibrillation, recent (<1 month) myocardial infarction or acute heart failure decompensation, clinically important liver insufficiency, combination with strong CYP3A4 inhibitors, Recent ICD implantation (<1 month). Women in fertile age without proper contraception, pregnant or breastfeeding women. Other concomitant illness which limits prognosis to less then 1 year. |
permanentní fibrilace síní, recentní užívání silných inhibitorů CYP3A4, klinicky významná jaterní insuficience, akutní dekompensace nebo srdeční infarkt v posledním měsíci. Implantace ICD v posledním měsíci. Jiné onemocnění limitující prognózu pacienta na méně než 1 rok. Těhotné anebo ženy ve fertilním věku bez účinné antikoncepce. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Decrease in arrhythmia incidence in the group treated with ivabradine
Decrease in ICD therapies delivered by ICD |
Snížení incidence supraventrikulárních a ventrikulárních arytmií v intervenované skupině
Snížení počtu ICD terapií
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 6 months and in 12 months |
po 6 měsících a po 12 měsících |
|
E.5.2 | Secondary end point(s) |
Hemodynamical effect of ivabradine evaluated clinically and echocardiographically |
Hemodynamický efekt ivabradinu hodnocený klinicky a echokardiograficky |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
At 6 months and in 12 months |
po 6 měsíích a 12 měsících |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |